European Union - English - EMA (European Medicines Agency)

teva pharma b.v. - repaglinide - diabetes mellitus, type 2 - drugs used in diabetes - repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (niddm)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. repaglinide is also indicated in combination with metformin in type-2-diabetes patients who are not satisfactorily controlled on metformin alone.treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.

European Union - English - EMA (European Medicines Agency)

krka, d.d., novo mesto - repaglinide - diabetes mellitus, type 2 - drugs used in diabetes - repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (niddm)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - repaglinide - tablet - 500microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - repaglinide - tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - repaglinide - tablet - 2mg

Israel - English - Ministry of Health

sanofi - aventis israel ltd - lixisenatide - solution for injection - lixisenatide 10 mcg / 0.2 ml - lixisenatide - for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Israel - English - Ministry of Health

sanofi - aventis israel ltd - lixisenatide - solution for injection - lixisenatide 20 mcg / 0.2 ml - lixisenatide - for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - tirzepatide - solution for injection - tirzepatide 20 mg/ml - tirzepatide - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications• in addition to other medicinal products for the treatment of diabetes.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - tirzepatide - solution for injection - tirzepatide 25 mg/ml - tirzepatide - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications• in addition to other medicinal products for the treatment of diabetes.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - tirzepatide - solution for injection - tirzepatide 30 mg/ml - tirzepatide - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications• in addition to other medicinal products for the treatment of diabetes.